SGHT Sight Sciences, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1531177 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.2%
TTM net income YoY38.4%
TTM EPS YoY42.2%
Revenue 3-yr CAGR2.2%
Net income 3-yr CAGR—
Margins
Gross margin87.7%
Operating margin-29.5%
Net margin-32.1%
FCF margin-19.1%
EBITDA margin-29.1%
Returns
ROE-50.1%
ROA-25.7%
ROIC (approx.)-166.6%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets53.2%
Debt / equity0.83x
Current ratio5.04x
Interest coverage-5.06x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue-0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.92M | $23.39M | $19.70M | $20.39M | $19.91M | $19.56M | $17.51M | $19.07M |
| Cost of revenue | $3.50M | $2.01M | $2.72M | $2.60M | $2.71M | $2.98M | $2.41M | $2.51M |
| Gross profit | $21.42M | $21.37M | $16.98M | $17.79M | $17.20M | $16.59M | $15.09M | $16.56M |
| R&D expense | $2.71M | $2.51M | $2.55M | $2.44M | $3.35M | $4.39M | $4.43M | $4.29M |
| SG&A expense | $24.84M | $22.75M | $26.84M | $19.02M | $21.75M | $23.87M | $24.52M | $24.20M |
| Operating income | -$6.13M | -$3.89M | -$12.41M | -$3.67M | -$7.91M | -$11.67M | -$13.86M | -$11.93M |
| Interest expense | $1.31M | $1.29M | $1.27M | $1.29M | $1.31M | $1.28M | $1.26M | $1.16M |
| Pretax income | -$6.80M | -$4.42M | -$12.97M | -$4.15M | -$8.25M | -$11.90M | -$14.11M | -$11.81M |
| Income tax | $11,000 | $28,000 | $11,000 | $8,000 | -$79,000 | $40,000 | $41,000 | $38,000 |
| Net income | -$6.81M | -$4.45M | -$12.98M | -$4.16M | -$8.17M | -$11.94M | -$14.15M | -$11.85M |
| EBITDA | -$6.03M | -$3.79M | -$12.31M | -$3.56M | -$7.80M | -$11.57M | -$13.71M | -$11.75M |
| EPS (basic) | -0.12 | -0.08 | -0.24 | — | -0.16 | -0.23 | -0.28 | — |
| EPS (diluted) | -0.12 | -0.08 | -0.24 | — | -0.16 | -0.23 | -0.28 | — |
| Weighted avg. shares (diluted) | 55.13M | 54.51M | 53.94M | — | 52.38M | 51.82M | 51.29M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $77.40M | $79.75M | $84.96M | $91.97M | $92.37M | $101.50M | $108.77M | $120.36M |
| Receivables | $13.38M | $11.39M | $10.60M | $9.74M | $9.74M | $9.61M | $9.42M | $10.79M |
| Inventory | $6.50M | $5.70M | $7.01M | $7.77M | $7.98M | $6.21M | $5.80M | $6.33M |
| Current assets | $101.47M | $101.44M | $106.51M | $112.73M | $113.59M | $119.43M | $126.91M | $139.77M |
| PP&E, net | $1.71M | $1.67M | $1.62M | $1.61M | $1.54M | $1.46M | $1.49M | $1.58M |
| Total assets | $104.95M | $104.87M | $109.70M | $115.30M | $116.26M | $121.97M | $129.68M | $142.84M |
| Current liabilities | $20.14M | $20.50M | $18.16M | $11.03M | $11.83M | $11.94M | $12.12M | $15.47M |
| Short-term debt | $6.06M | $10.13M | $3.80M | $0 | $0 | $0 | $0 | $0 |
| Long-term debt | $34.97M | $30.64M | $42.38M | $40.30M | $40.07M | $39.82M | $39.58M | $39.36M |
| Total debt | $41.03M | $40.78M | $46.18M | $40.30M | $40.07M | $39.82M | $39.58M | $39.36M |
| Total liabilities | $55.81M | $51.98M | $55.80M | $51.36M | $51.97M | $51.96M | $52.05M | $55.32M |
| Shareholders' equity | $49.14M | $52.89M | $53.90M | $63.94M | $64.29M | $70.01M | $77.63M | $87.52M |
| Net debt | -$36.37M | -$38.98M | -$38.78M | -$51.66M | -$52.30M | -$61.68M | -$69.19M | -$81.00M |
| Shares outstanding | 55.22M | 54.72M | 54.03M | 53.49M | 52.47M | 52.03M | 51.38M | 50.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.40M | -$5.66M | -$7.03M | -$1.83M | -$8.72M | -$7.54M | -$11.61M | -$3.46M |
| Capital expenditure | $68,000 | $19,000 | $60,000 | -$156,000 | $170,000 | $210,000 | $0 | $137,000 |
| Free cash flow | -$2.47M | -$5.68M | -$7.09M | -$1.67M | -$8.89M | -$7.75M | -$11.61M | -$3.60M |
| Investing cash flow | -$68,000 | -$19,000 | -$60,000 | $156,000 | -$170,000 | -$210,000 | $0 | -$137,000 |
| Financing cash flow | $119,000 | $474,000 | $88,000 | $1.26M | $25,000 | $485,000 | $16,000 | $5.39M |
| Depreciation & amortization | $100,000 | $100,000 | $103,000 | $108,000 | $100,000 | $100,000 | $149,000 | $176,000 |
| Stock-based compensation | $2.94M | $2.96M | $2.85M | $2.55M | $2.42M | $3.84M | $4.24M | $3.95M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.